Inhibition of the replication of hepatitis B virus in vitro by a novel 2,6-diaminopurine analog, β-LPA

Biochemical and Biophysical Research Communications

Volumn 369, Issue 2, 2008, Pages 513-518

  He, Xing Xing ^a   Chen, Ting ^a   Lin, Ju Sheng ^a   Chang, Ying ^a   Ye, Bai Xin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antiviral therapy; Chronic hepatitis B; Hepatitis B virus; Nucleoside analog

Indexed keywords

2,6 DIAMINOPURINE DERIVATIVE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MITOCHONDRIAL DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DNA CONTENT; DNA SYNTHESIS; DRUG INHIBITION; DRUG STRUCTURE; HEPATITIS B VIRUS; PRIORITY JOURNAL; VIRUS REPLICATION;

2-AMINOPURINE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATITIS B VIRUS; HUMANS; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 40849135565     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.02.039     Document Type: Article

References (36)

1. Sun Z., Ming L., Zhu X., and Lu J. Prevention and control of hepatitis B in China. J. Med. Virol. 67 (2002) 47-50
2. Kao J.H., and Chen D.S. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2 (2002) 395-403
3. Robertson S.E., Mayans M.V., El-Husseiny A., Clemens J.D., and Ivanoff B. The WHO vaccine trial registry. Vaccine 20 (2001) 31-41
4. Ocama P., Opio C.K., and Lee W.M. Hepatitis B virus infection: current status. Am. J. Med. 118 (2005) 1413
5. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
6. Liaw Y.F. Therapy of chronic hepatitis B: current challenges and opportunities. J. Viral. Hepat. 9 (2002) 393-399
7. Ganem D., and Varmus H.E. The molecular biology of the hepatitis B viruses. Annu. Rev. Biochem. 56 (1987) 651-693
8. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., and Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 119 (1993) 312-323
9. Manns M.P. Current state of interferon therapy in the treatment of chronic hepatitis B. Semin. Liver Dis. 22 Suppl. 1 (2002) 7-13
10. Zoulim F., Poynard T., Degos F., Slama A., El Hasnaoui A., Blin P., Mercier F., Deny P., Landais P., Parvaz P., Trepo C., and The Lamivir Study Group. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J. Viral. Hepat. 13 (2006) 278-288
11. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., Plym M., Pokornowski K., Yu C.F., Angus P., Ayres A., Bartholomeusz A., Sievert W., Thompson G., Warner N., Locarnini S., and Colonno R.J. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 48 (2004) 3498-3507
12. Hawkins A.E., Zuckerman M.A., Briggs M., Gilson R.J., Goldstone A.H., Brink N.S., and Tedder R.S. Hepatitis B nucleotide sequence analysis: linking an outbreak of acute hepatitis B to contamination of a cryopreservation tank. J. Virol. Methods 60 (1996) 81-88
13. Tennant B.C., Baldwin B.H., Graham L.A., Ascenzi M.A., Hornbuckle W.E., Rowland P.H., Tochkov I.A., Yeager A.E., Erb H.N., Colacino J.M., Lopez C., Engelhardt J.A., Bowsher R.R., Richardson F.C., Lewis W., Cote P.J., Korba B.E., and Gerin J.L. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 28 (1998) 179-191
14. Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res. 71 (2006) 206-215
15. Xu X.W., and Chen Y.G. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B. Hepatobiliary Pancreat. Dis. Int. 5 (2006) 350-359
16. Chu C.K., Boudinot F.D., Peek S.F., Hong J.H., Choi Y., Korba B.E., Gerin J.L., Cote P.J., Tennant B.C., and Cheng Y.C. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir. Ther. 3 (1998) 113-121
17. Colacino J.M. Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU). Antiviral Res. 29 (1996) 125-139
18. Lin J.S., Kira T., Gullen E., Choi Y., Qu F., Chu C.K., and Cheng Y.C. Structure-activity relationships of l-dioxolane uracil nucleosides as anti-Epstein Barr virus agents. J. Med. Chem. 42 (1999) 2212-2217
19. Ma T., Pai S.B., Zhu Y.L., Lin J.S., Shanmuganathan K., Du J., Wang C., Kim H., Newton M.G., Cheng Y.C., and Chu C.K. Structure-activity relationships of 1-(2-Deoxy-2-fluoro-beta-l-arabinofuranosyl) pyrimidine nucleosides as anti-hepatitis B virus agents. J. Med. Chem. 39 (1996) 2835-2843
20. Kotra L.P., Xiang Y., Newton M.G., Schinazi R.F., Cheng Y.C., and Chu C.K. Structure-activity relationships of 2-deoxy-2, 2-difluoro-l-erythro-pentofuranosyl nucleosides. J. Med. Chem. 40 (1997) 3635-3644
21. Qiu Y.L., Ptak R.G., Breitenbach J.M., Lin J.S., Cheng Y.C., Kern E.R., Drach J.C., and Zemlicka J. (Z)- and (E)-2-(hydroxymethylcyclopropylidene)-methylpurines and pyrimidines as antiviral agents. Antivir. Chem. Chemother. 9 (1998) 341-352
22. Qiu Y.L., Ksebati M.B., Ptak R.G., Fan B.Y., Breitenbach J.M., Lin J.S., Cheng Y.C., Kern E.R., Drach J.C., and Zemlicka J. (Z)- and (E)-2-((hydroxymethyl) cyclopropylidene) methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity. J. Med. Chem. 41 (1998) 10-23
23. Du J., Surzhykov S., Lin J.S., Newton M.G., Cheng Y.C., Schinazi R.F., and Chu C.K. Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides. J. Med. Chem. 40 (1997) 2991-2993
24. Lu X., Gong S., Monks A., Zaharevitz D., and Moscow J.A. Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity. J. Exp. Ther. Oncol. 2 (2002) 200-212
25. Hostetler K.Y., Korba B.E., Sridhar C.N., and Gardner M.F. Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice. Antiviral Res. 24 (1994) 59-67
26. Innaimo S.F., Seifer M., Bisacchi G.S., Standring D.N., Zahler R., and Colonno R.J. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41 (1997) 1444-1448
27. Seigneres B., Pichoud C., Martin P., Furman P., Trepo C., and Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36 (2002) 710-722
28. Dalakas M.C., Semino-Mora C., and Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab. Invest. 81 (2001) 1537-1544
29. Wang X.Y., Gao L.L., Deng F., Zhang Y.F., Li Y., and Lin J.S. High-level production of a functional recombinant hepatitis B virus polymerase in insect cells with a baculovirus expression system. J. Huazhong Univ. Sci. Technol. Med. Sci. 27 (2007) 269-273
30. Ashton W.T., Meurer L.C., Cantone C.L., Field A.K., Hannah J., Karkas J.D., Liou R., Patel G.F., Perry H.C., and Wagner A.F. Synthesis and antiherpetic activity of (+/-)-9-[[(Z)-2-(hydroxymethyl)cyclopropyl]methyl]guanine and related compounds. J. Med. Chem. 31 (1988) 2304-2315
31. Barrish J.C., and Zahler R. Antivir. Agents. Annu. Rep. Med. Chem. 28 (1993) 131-140
32. Balzarini J., Karlsson A., Aquaro S., Perno C.F., Cahard D., Naesens L., De Clercq E., and McGuigan C. Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proc. Natl. Acad. Sci. 93 (1996) 7295-7299
33. Lai C.L., Dienstag J., Schiff E., Leung N.W., Atkins M., Hunt C., Brown N., Woessner M., Boehme R., and Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36 (2003) 687-696
34. Lok A.S., Lai C.L., Leung N., Yao G.B., Cui Z.Y., Schiff E.R., Dienstag J.L., Heathcote E.J., Little N.R., Griffiths D.A., Gardner S.D., and Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
35. Zoulim F., Poynard T., Degos F., Slama A., El Hasnaoui A., Blin P., Mercier F., Deny P., Landais P., Parvaz P., Trepo C., and The Lamivir Study Group. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J. Viral Hepat. 13 (2006) 278-288
36. Zhu Y., Yamamoto T., Cullen J., Saputelli J., Aldrich C.E., Miller D.S., Litwin S., Furman P.A., Jilbert A.R., and Mason W.S. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J. Virol. 75 (2001) 311-322